Larotrectinib in Adjuvant and First-Line Treatment for Metastatic NTRK Fusion Colon Cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
surgery for colon cancer, with recurrent bleeding from the tumor, and subcompensated intestinal stenosis
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
At the time of this clinical case report, therapy is ongoing for 21 months without any signs of further disease progression. This study demonstrates the efficacy and safety of larotractinib as both adjuvant therapy and first-line therapy in a complex clinical case of colon cancer against the background of severe concomitant pathology, when chemotherapy is contraindicated.
We report an 83-year-old woman with severe concomitant pathology who underwent surgery for colon cancer, with recurrent bleeding from the tumor, and subcompensated intestinal stenosis.
APA
Volkov AY, Pylev AL, et al. (2026). Larotrectinib in Adjuvant and First-Line Treatment for Metastatic NTRK Fusion Colon Cancer.. Asia-Pacific journal of clinical oncology. https://doi.org/10.1111/ajco.70072
MLA
Volkov AY, et al.. "Larotrectinib in Adjuvant and First-Line Treatment for Metastatic NTRK Fusion Colon Cancer.." Asia-Pacific journal of clinical oncology, 2026.
PMID
41571604 ↗
Abstract 한글 요약
We report an 83-year-old woman with severe concomitant pathology who underwent surgery for colon cancer, with recurrent bleeding from the tumor, and subcompensated intestinal stenosis. After right-sided hemicolectomy with regional lymph node dissection, the disease was staged as pIIIC, and a translocation of the NTRK1 (Neurotrophic Tyrosine Receptor Kinase) gene was detected. The patient required adjuvant treatment, given the high risk of disease progression, but due to her severe concomitant pathology, chemotherapy was contraindicated. Adjuvant therapy with larotrectinib was recommended given NTRK gene translocation. According to examination data after three months, there was no progression. Following this, the patient decided to stop larotrectinib. Subsequently, disease progression was detected in the form of abdominal carcinomatosis, after which larotrectinib was resumed. At the time of this clinical case report, therapy is ongoing for 21 months without any signs of further disease progression. This study demonstrates the efficacy and safety of larotractinib as both adjuvant therapy and first-line therapy in a complex clinical case of colon cancer against the background of severe concomitant pathology, when chemotherapy is contraindicated.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Systemic Inflammation and Survival in Stage IV Colorectal Cancer: A Retrospective Cohort Study.
- A subset of MMR-proficient colon cancers responds to neoadjuvant immunotherapy.
- Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study.
- Liver Abscess as the Herald of Underlying Colorectal Neoplasm.
- Compliance and Quality of Endoscopic Tattooing in Colorectal Cancer: A Retrospective Audit.
- NTRK2 promotes malignant progression and paclitaxel resistance of lung adenocarcinoma through targeting MYC/ABCF1 axis.